We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients.
- Authors
Maneenil, Kunlatida; Zhiqiang Xue; Ming Liu; Boland, Jennifer; Fengying Wu; Stoddard, Shawn M.; Molina, Julian; Ping Yang; Xue, Zhiqiang; Liu, Ming; Wu, Fengying; Yang, Ping
- Abstract
<bold>Background: </bold>Pulmonary sarcomatoid carcinoma (PSC) is an unusual form of non-small-cell lung cancer (NSCLC). Because of its rarity and heterogeneity, the treatment and prognosis of PSC have not been clearly described.<bold>Methods and Materials: </bold>We retrospectively evaluated all patients with a diagnosis of PSC from 1997 to 2015 at the Mayo Clinic (Rochester, MN). The clinical characteristics, treatment details, and outcomes were collected. The survival rates of the PSC patients were compared with those for other subtypes of NSCLC. We used propensity score matching to minimize the bias resulting from to imbalanced comparison groups.<bold>Results: </bold>The study included 127 PSC patients. The median age at diagnosis was 68 years (range, 32-89 years), most of whom were men (61%) and smokers (82%). The clinical stage was I, II, III, and IV in 15.9%, 20.6%, 22.2%, and 41.3%, respectively. The median survival time was 9.9 months (95% confidence interval [CI], 7.6-12.6 months). The 1-, 2-, and 5-year survival rates were 42%, 23%, and 15%, respectively. Most patients received multimodality treatment. Of the 3 patients who received neoadjuvant chemotherapy, a partial response was demonstrated in 2. Twenty-five patients who underwent palliative chemotherapy were evaluated for tumor response: 52% experienced progression, 40% stable disease, 8.0% a partial response, and 0% a complete response. Multivariate analysis showed T stage, M stage, and treatment with surgery plus neoadjuvant chemotherapy or surgery plus adjuvant therapy were independent prognostic factors (P < .05). In matched analysis, multivariate models revealed worse overall survival for PSC compared with adenocarcinoma (hazard ratio, 2.38; 95% CI, 1.61-2.53) and squamous cell carcinoma (hazard ratio, 2.20; 95% CI, 1.44-2.34).<bold>Conclusion: </bold>We found the outcome of PSC to be significantly worse than that of adenocarcinoma and squamous cell carcinoma. Neoadjuvant or adjuvant chemotherapy, in addition to surgical resection, should be considered.
- Subjects
LUNG cancer treatment; TREATMENT of lung tumors; COMBINED modality therapy; COMPARATIVE studies; LUNG cancer; LUNG tumors; RESEARCH methodology; MEDICAL cooperation; RESEARCH; RESEARCH funding; EVALUATION research; RETROSPECTIVE studies
- Publication
Clinical Lung Cancer, 2018, Vol 19, Issue 3, pe323
- ISSN
1525-7304
- Publication type
journal article
- DOI
10.1016/j.cllc.2017.12.008